Pixantrone; nilotinib

Hospital Pharmacy

Volumn 42, Issue 4, 2007, Pages 297-303

  Higdon, Jamie E ^c   Waddell, J Aubrey ^b,c   Solimando Jr , Dominic A ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

^c BLOUNT MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; NILOTINIB; PIXANTRONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE LYMPHOCYTIC LEUKEMIA; ALOPECIA; ANEMIA; ARTHRALGIA; ARTHRITIS; ASTHENIA; BONE PAIN; CANCER CHEMOTHERAPY; CHILL; CONSTIPATION; COUGHING; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRY SKIN; DYSPNEA; ENDOCARDITIS; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPEREOSINOPHILIC SYNDROME; LEUKEMIA; LEUKOCYTOSIS; LYMPHOCYTOPENIA; MASTOCYTOSIS; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PRURITUS; RASH; REVIEW; SEPSIS; SEPTICEMIA; SIDE EFFECT; SKIN DISCOLORATION; SORE THROAT; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 34247390722     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4204-297     Document Type: Review

References (24)

1. Faivre S, Raymond E, Boige V, et al. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Clin Cancer Res. 2001;7:43-50.
2. Dawson LK, Jodrell DI, Bowman A, et al. A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. Eur J Cancer. 2000;36:2353-2359.
3. Borchmann P, Schnell R, Knippertz R, et al. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann Oncol. 2001;12:661-667.
4. Bernareggi A, Torti L, Ratti E, et al. Clinical pharmacokinetics of BBR 2778 in patients with malignant lymphoma [abstract]. American Society of Clinical Oncology. Available at: http://www.asco.org/portal/site/ASCO/menuitem. 34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010Vgn- VCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=17&abstractID= 14981. Accessed February 27, 2007.
5. Camboni G, Fayad L, Tulpule A, et al. A phase I/II trial of BBR-2778 (pixantrone), methylprednisolone, cisplatin, and cytosine arabinoside (BSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) [abstract]. J Clin Oncol (ASCO Annual Meeting Proceedings). 2004;22 (suppl 14):6590.
6. Fayad L, Liebmann J, Modiano M, et al. Results of a Phase I/II trial of pixantrone in combination with fludarabine, dexamethasone, and rituximab in the treatment of patients with relapsed/refractory indolent non-Hodgkin's lymphoma (NHL) [abstract]. Blood. 2006;108:2758.
7. Borchmann P, Herbrecht R, Wilhelm M, et al. Results of a Phase II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma [abstract]. Blood. 2006;108:529.
8. Borchmann P, Morschhauser F, Parry A, et al. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. Haematologica. 2003;88:888-894.
9. Santoro A, Voglova J, Gabrail N, et al. Comparative trial of BBR 2778 (pixantrone) + rituximab vs single agent rituximab in the treatment of relapsed/ refractory indolent non-Hodgkin's lymphoma (NHL) [abstract]. J Clin Oncol (ASCO Annual Meeting Proceedings). 2006;24(suppl 18S):7578.
10. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia Chromosome-positive ALL. N Engl J Med. 2006;354:2542-2551.
11. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129-141.
12. Weisberg E, Manley P, Mestan J, Cowan-Jacobs, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006;94:1765-1769.
13. Jabbour E, Cortes J, Kantarjian H. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. Curr Opin Oncol. 2006;18:578-583.
14. Ottmann O, Kantarjian H, Larson R, et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL) [abstract]. Blood. 2006;108:1862.
15. Giles F, Le Coutre P, Bhalla K, et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib [abstract]. Blood. 2006;108:2170.
16. Hochhaus A, Ottmann O, Lauber S, et al. A phase II study of nilotinib, a novel inhibitor of c-Kit, PDGFR, and Bcr-Abl, administered to patients with systemic mastocytosis [abstract]. Blood. 2006;108:2703.
17. Kantarjian HM, Gattermann N, Hochhaus A, et al. A Phase II study of nilotinib a novel tyrosine kinase inhibitor administered to imatinib-resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP) [abstract]. Blood. 2006;108:2169.
18. Giles FJ, Larson R, Le Coutre P, et al. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL) [abstract]. J Clin Oncol (ASCO Annual Meeting Proceedings). 2006;24(suppl 18S):6536.
19. Le Coutre PD, Ottman O, Gatterman N, et al. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP) [abstract]. J Clin Oncol (ASCO Annual Meeting Proceedings). 2006;24(suppl 18S):6531.
20. Kantarjian HM, Gattermann N, O'Brien SG, et al. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) [abstract]. J Clin Oncol (ASCO Annual Meeting Proceedings). 2006;24(suppl 18S):6534.
21. Jabbour E, Cortes J, Giles F, et al. Preliminary activity of nilotinib (AMN107), a novel selective potent oral Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP) [abstract]. Blood. 2006;108:2172.
22. Le Coutre P, Bhalla K, Giles F, et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP) [abstract]. Blood. 2006;108:165.
23. Jabbour E, Kantarjian H, Giles F, et al. Treatment with nilotinib for patients with chronic myeloid leukemia (CML) who failed prior therapy with imatinib and dasatinib [abstract]. Blood. 2006;108:2171.
24. Le Coutre P, Hochhaus A, Heim D, et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with hypereosiniphilic syndrome (HES) [abstract]. Blood. 2006;108:4912.